Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men aged 18-55 yrs.~* Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2010 revision of the McDonald Criteria.~* Expanded Disability Status Scale (EDSS) between 0-5, inclusive.~Exclusion Criteria:~* Relapse episode of MS within 2 weeks of enrollment.~* Primary progressive MS without a relapsing component.~* Intolerant or unwilling to undergo MRI scanning. Treatment with disease modifying agents up to 6 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): None
- PF-06342674 1.5 mg/kg (Type: EXPERIMENTAL): None
- PF-06342674 6.0 mg/kg (q2 Weeks) (Type: EXPERIMENTAL): None
- PF-06342674 6.0 mg/kg (q1 Week) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).